KRW 15970.0
(-0.19%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 238.12 Million KRW | -13.2% |
2022 | 274.35 Million KRW | 51.52% |
2021 | 181.06 Million KRW | -58.99% |
2020 | 441.5 Million KRW | 249.01% |
2019 | 126.5 Million KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | 0.0% |
2013 | - KRW | -100.0% |
2012 | 1.5 Billion KRW | -57.14% |
2011 | 3.5 Billion KRW | -30.0% |
2010 | 5 Billion KRW | 66.67% |
2009 | 3 Billion KRW | 0.0% |
2008 | - KRW | 0.0% |
2007 | - KRW | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 196.3 Million KRW | -15.59% |
2024 Q1 | 232.57 Million KRW | -2.33% |
2023 Q4 | 238.12 Million KRW | -15.88% |
2023 Q1 | 169.26 Million KRW | -38.3% |
2023 FY | 238.12 Million KRW | -13.2% |
2023 Q3 | 283.08 Million KRW | 42.13% |
2023 Q2 | 199.17 Million KRW | 17.67% |
2022 Q2 | 298.94 Million KRW | 79.29% |
2022 Q1 | 166.74 Million KRW | -7.91% |
2022 FY | 274.35 Million KRW | 51.52% |
2022 Q4 | 274.35 Million KRW | -19.39% |
2022 Q3 | 340.32 Million KRW | 13.84% |
2021 Q2 | 341.27 Million KRW | -8.79% |
2021 FY | 181.06 Million KRW | -58.99% |
2021 Q4 | 181.06 Million KRW | -30.77% |
2021 Q1 | 374.18 Million KRW | -15.25% |
2021 Q3 | 261.54 Million KRW | -23.36% |
2020 Q2 | 509.73 Million KRW | 416.87% |
2020 Q1 | 98.61 Million KRW | -22.04% |
2020 Q3 | 497.59 Million KRW | -2.38% |
2020 FY | 441.5 Million KRW | 249.01% |
2020 Q4 | 441.5 Million KRW | -11.27% |
2019 Q2 | 182.19 Million KRW | -8.22% |
2019 Q4 | 126.5 Million KRW | -18.04% |
2019 FY | 126.5 Million KRW | 0.0% |
2019 Q1 | 198.5 Million KRW | 0.0% |
2019 Q3 | 154.34 Million KRW | -15.28% |
2018 FY | - KRW | 0.0% |
2018 Q2 | - KRW | 0.0% |
2018 Q4 | - KRW | 0.0% |
2018 Q1 | - KRW | 0.0% |
2018 Q3 | - KRW | 0.0% |
2017 Q3 | - KRW | 0.0% |
2017 Q1 | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2017 Q4 | - KRW | 0.0% |
2017 Q2 | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2015 Q2 | - KRW | 0.0% |
2015 Q3 | - KRW | 0.0% |
2015 Q4 | - KRW | 0.0% |
2015 FY | - KRW | 0.0% |
2015 Q1 | - KRW | 0.0% |
2014 Q3 | - KRW | 0.0% |
2014 Q2 | - KRW | 0.0% |
2014 FY | - KRW | 0.0% |
2014 Q4 | - KRW | 0.0% |
2014 Q1 | - KRW | 0.0% |
2013 Q3 | - KRW | -100.0% |
2013 Q4 | - KRW | 0.0% |
2013 FY | - KRW | -100.0% |
2013 Q1 | 4.4 Billion KRW | 193.33% |
2013 Q2 | 2.9 Billion KRW | -34.09% |
2012 Q4 | 1.5 Billion KRW | 0.0% |
2012 Q3 | 1.5 Billion KRW | 0.0% |
2012 Q2 | 1.5 Billion KRW | 0.0% |
2012 FY | 1.5 Billion KRW | -57.14% |
2012 Q1 | 1.5 Billion KRW | -57.14% |
2011 Q3 | 2 Billion KRW | 0.0% |
2011 Q1 | 5 Billion KRW | 0.0% |
2011 Q2 | 2 Billion KRW | -60.0% |
2011 FY | 3.5 Billion KRW | -30.0% |
2011 Q4 | 3.5 Billion KRW | 75.0% |
2010 Q2 | - KRW | 0.0% |
2010 Q1 | - KRW | -100.0% |
2010 Q4 | 5 Billion KRW | 0.0% |
2010 Q3 | - KRW | 0.0% |
2010 FY | 5 Billion KRW | 66.67% |
2009 Q4 | 3 Billion KRW | 0.0% |
2009 Q3 | 3 Billion KRW | -40.0% |
2009 Q2 | 5 Billion KRW | 0.0% |
2009 Q1 | 5 Billion KRW | 0.0% |
2009 FY | 3 Billion KRW | 0.0% |
2008 Q1 | 10.71 Billion KRW | 0.0% |
2008 Q2 | 9.36 Billion KRW | -12.52% |
2008 FY | - KRW | 0.0% |
2008 Q3 | - KRW | -100.0% |
2008 Q4 | - KRW | 0.0% |
2007 Q2 | - KRW | 0.0% |
2007 Q3 | - KRW | 0.0% |
2007 FY | - KRW | 0.0% |
2007 Q4 | - KRW | 0.0% |
2007 Q1 | - KRW | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 99.507% |
Yuhan Corporation | 230.07 Billion KRW | 99.896% |
Yuhan Corporation | 230.07 Billion KRW | 99.896% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | 99.396% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | 99.396% |
Yuyu Pharma, Inc. | 39.4 Billion KRW | 99.396% |
Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 99.938% |
Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 99.865% |
Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 99.966% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.86% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.86% |
JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.86% |
SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | 60.011% |
Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 99.949% |
Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 99.45% |
HANDOK Inc. | 300.01 Billion KRW | 99.921% |
Jeil Pharma Holdings Inc | 173.03 Billion KRW | 99.862% |
Kukje Pharma Co., Ltd. | 30.66 Billion KRW | 99.223% |
Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 99.7% |
Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 99.868% |
Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 99.837% |
Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 99.644% |
Boryung Corporation | 204.21 Billion KRW | 99.883% |
Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | 99.393% |
Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 99.799% |
Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 99.72% |
Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 99.72% |
Suheung Co., Ltd. | 467.85 Billion KRW | 99.949% |
Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 99.899% |
Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | 81.548% |
Whan In Pharm Co.,Ltd. | 632.02 Million KRW | 62.323% |
MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 99.737% |
Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 99.484% |
Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 99.484% |
Korea United Pharm Inc. | 40.33 Billion KRW | 99.41% |
CKD Bio Corp. | 146.92 Billion KRW | 99.838% |
Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 99.949% |
JW Holdings Corporation | 554.58 Billion KRW | 99.957% |
REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 99.894% |
Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 99.958% |
Dong-A ST Co., Ltd. | 406.7 Billion KRW | 99.941% |
Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 99.892% |
JW Lifescience Corporation | 46.31 Billion KRW | 99.486% |
Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 99.891% |
Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 99.72% |
Hana Pharm Co., Ltd. | 26.53 Billion KRW | 99.103% |